Since the majority of NSCLC patients are initially diagnosed at an advanced stage, a small biopsy or cytological tumor samples are typically obtained for histological typing and biomarker evaluation, which is a barrier to PD-L1 testing 8. The gene discussed is CD274; the disease is neoplasm.